Objective: To investigate the relationship between antiepileptic drug (AED) polytherapy in pregnant women and the risk of fetal malformations as prescribing practice changed, with valproate being used less often and at lower doses. Specifically, the risks associated with two of the most common AEDs included in polytherapy over recent years, levetiracetam and topiramate, were examined. Methods: An observational cohort study in which malformation rates were analyzed in 1,461 pregnancies exposed to AED monotherapy, and in 484 exposed to antiepileptic drug combinations, from the Australian Register of Antiepileptic Drugs in Pregnancy over a 15-year period (1999-2014). Results: Fetal malformation rates had fallen over time in monotherapy pregnancies, but increased in polytherapy pregnancies, despite decreasing use and lower dosages of valproate. The rise in polytherapy malformation rates began around 2005 when levetiracetam and topiramate use began to increase. Excluding pregnancies involving valproate exposure, malformation rates were higher in the remaining polytherapy pregnancies as compared with the monotherapy ones (6.90% vs. 3.64%; odds ratio [OR] 1.96, 95% confidence interval [CI] 1.14-3.39). Malformation rates were similar in polytherapy pregnancies whether or not levetiracetam was included (7.14% vs. 8.38%), but were higher in polytherapy pregnancies involving topiramate (14.94% vs. 6.55%: OR 2.507, 95% CI 1.23-5.10). Logistic regression showed that topiramate in polytherapy had a positive dose relationship with teratogenicity risk (p = 0.025). Significance: The malformation risk associated with AED polytherapy depends on the specific drugs involved. Topiramate, when used as part of AED polytherapy that did not include valproate, was associated with a dose-related increased risk of fetal malformations. KEY WORDS: AED polytherapy, Fetal malformation, Levetiracetam, Topiramate, Valproate.
After the association between antiepileptic drug (AED) exposure during pregnancy and the occurrence of fetal malformations was recognized, several investigations reported that the risk of such malformations was greater when combinations of antiepileptic drugs were employed in pregnant women than when only a single antiepileptic drug was involved. [1] [2] [3] [4] [5] As a consequence, the belief was expressed that prescribing AED combinations in pregnant women should be avoided as far as possible. Then, in 2010 and 2011, three articles appeared in the literature, including one from our group, each demonstrating that the critical factor that determined the increased malformation risk associated with AED polytherapy was not the use of two drugs simultaneously per se, but the inclusion of valproate-by this time known to be a dose-dependent teratogen-in the combinations. [6] [7] [8] Because prescribing practice in pregnant women with epilepsy has changed over the last decade and valproate is now being employed less often and at lower doses, 9, 10 we wished to reexamine the relationship between AED polytherapy and the risk of fetal malformations, focusing on AED combinations that did not involve valproate. Specifically it was hypothesized that AEDs other than valproate may contribute to an increased malformation risk of AED polytherapy in pregnancy.
Methods
This investigation is based on the data for the outcomes of completed pregnancies recorded in the Australian Pregnancy Register from 1999 to the end of 2014. The nature of and data collecting policies and practices of the register, and its ethics oversight, have been described previously. 11 In brief, enrollment in the register is open to pregnant women throughout Australia who have epilepsy, whether treated with AEDs or left untreated, and also to those who are taking AEDs for some indication other than epilepsy. Inclusion in the register is at the initiative of the pregnant women themselves after they are made aware of its existence by their treating medical practitioners, nurses, or allied health professionals, or other women who know of the register. Once women are enrolled, all further contact with the register is by telephone. Details of pregnancy are obtained at recruitment, usually in the first or second trimester, again at 7 months of pregnancy, in the first postnatal month, and finally, whenever feasible, 1 year after childbirth. All women enrolled in the register provide written informed consent before any data are collected, and the register is approved by the Human Research and Ethics Committee of Melbourne Health, the current host institution.
The register has been collecting data since 1999, and by the end of 2014 contained details of 1,461 pregnancies in women who had taken a single AED, 484 pregnancies of women who had taken two or more AEDs simultaneously, and 159 women who had taken no AEDs in at least the first trimester of pregnancy, the period when fetal malformations are likely to develop. The relevant information was transferred from a Microsoft Access database to a Microsoft Excel spreadsheet (Microsoft Corp.) and then analyzed by conventional statistical methods, viz. confidence interval and logistic regression techniques.
Results
Plotting the mean valproate dose taken by pregnant women in the Australian Pregnancy Register in the first trimester of pregnancy against year of the last menstrual period before becoming pregnant (Fig. 1, top panel) demonstrated that over time the mean dosages of valproate had decreased when used in monotherapy (p = 0.0012) and tended to decrease when used in polytherapy (p = 0.0765). There also was a significant decrease in prescription of the drug, as a proportion of overall AED prescribing, for valproate monotherapy (p = 0.007), and a trend (p = 0.085) when the drug was used as part of AED combinations ( Fig. 1, middle panel) . Along with the decreased dosage and decreased use of valproate in monotherapy, there was a statistically significant fall in the associated fetal malformation rate in monotherapy pregnancies, the rate almost reaching the 3.14% figure that applied for the 159 drugunexposed pregnancies (Fig. 1, lower panel) . In contrast, instead of the anticipated decrease in the malformation rate in the AED polytherapy pregnancies, the actual rate had increased, although not in a statistically significant fashion, with time, and there was an obvious change in the behavior of the malformation rate in the polytherapy pregnancies which had begun later than 2005. There was a statistically significant difference in the slope of the two regressions in the lowest panel. This unexpected behavior in malformation rates required investigation. It appeared that some circumstance might have arisen during the time period studied that had altered the behavior of the fetal malformation rate associated with AED combination use.
In the register data examined, the overall fetal malformation rate was just significantly higher in the polytherapy pregnancies (N = 484) than in the 1,461 monotherapy ones (8.06% vs. 5.48%; odds ratio [OR] 1.51, 95% confidence interval [CI] 1.02-2.25). If the comparison was restricted to pregnancies in the two groups in which there had been exposure to valproate, the malformation rate when another AED was present was 9.79% in 194 polytherapy pregnancies, but 13.26% in 279 pregnancies where the drug was used in monotherapy (OR 0.71, 95% CI 0.40-1.28), a nonstatistically significant difference. The mean valproate doses in the two groups, 895 AE (standard deviation) 653 mg/day and 945 AE 634 mg/day, were not significantly different (difference = 50 mg/day; 95% CI À67.9 to 168 mg/day). However, in the 290 polytherapy treated pregnancies in which there was no valproate exposure, the malformation rate was 6.90%, higher than the 3.64% rate in 1,182 pregnancies exposed to monotherapy with an Key Points • Teratogenicity of antiepileptic drugs other than valproate was examined
• Data were analyzed from 484 women exposed to polytherapy from the Australian Register of Antiepileptic Drugs in Pregnancy
• Even after exclusion of valproate, fetal malformation (FM) rates were higher in polytherapy exposures than for monotherapy
• Levetiracetam exposure in polytherapy did not result in increased malformation rates
• Logistic regression indicated that risk was higher for FM rates in polytherapy pregnancies involving topiramate, in a dose-related manner AED other than valproate, and this difference was statistically significant (OR 1.96, 95% CI 1.14-3.39). Thus the combinations of AEDs that did not include valproate were associated with significantly more frequent fetal malformations than pregnancies exposed to single AEDs apart from valproate. It therefore seemed likely that a teratogen other than valproate was involved in the increased rate of malformations that has developed with time in the AED polytherapy-exposed pregnancies.
Inspection of the annual rate of malformations in AED polytherapy-exposed pregnancies (lower panel of Fig. 1) indicates that the fetal malformation rate had tended to increase rather abruptly in pregnancies that had begun around 2005. The data in Figure 2 show that, in around 2003 (i.e., for pregnancies mostly ending in 2004), the use of lamotrigine had tended to decrease to some extent but the use of levetiracetam and topiramate had begun to increase. The increase in the former was progressive but in the latter it had tended to flatten out or begin to diminish toward the end of the period studied. With a suspicion that a second teratogen was involved in the AED polytherapy-associated pregnancies, the possible roles of levetiracetam and topiramate were examined.
In the 358 AED polytherapy pregnancies in which there had been no exposure to levetiracetam, the fetal malformation rate was 8.38%, whereas in the 126 polytherapy pregnancies in which there had been levetiracetam exposure, the malformation rate was 7.14% (OR 1.19, 95% CI 0.55-2.58). This finding made levetiracetam an unlikely candidate for a role of teratogen in the AED combinations. On the other hand, in the 87 pregnancies in which topiramate had been part of the combinations, there was a 14.94% fetal malformation rate, in contrast to the 6.55% rate in the 397 polytherapy pregnancies in which there was no topiramate Proportions of all pregnancies exposed to particular antiepileptic drugs used in polytherapy related to the year of the last menstrual period before the enrolled pregnancy. CBZ, carbamazepine; LEV, levetiracetam; LTG, lamotrigine; TPM, topiramate; VPA, valproate. Epilepsia ILAE Epilepsia, 57 (7):1048-1052, 2016 doi: 10.1111/epi.13415 exposure (OR 2.51, 95% CI 1.23-5.10). Thus the evidence pointed to topiramate acting as a teratogen in the AED combinations studied, although it should be noted that the malformation rate associated with topiramate use in monotherapy in 48 pregnancies in the register was not higher than the malformation rate for the untreated pregnancies (2.08 vs. 3.14%). There were too few topiramate-associated pregnancies each year to permit determination of annual malformation rate trends in these pregnancies.
Logistic regression analysis showed that this was the case for the drug used in polytherapy (Fig. 3) , but there were too few malformations to explore such a relationship in the case of topiramate monotherapy. This dose relatedness of the topiramate associated malformation rate in polytherapy raised the question as to whether the difference between the topiramate monotherapy and polytherapy data might be accounted for by topiramate dosage differences between the two groups. The mean topiramate dose was 186.9 AE 116.9 mg per day (median 113, range 6.25-400 mg/day) for the monotherapy exposed pregnancies, and 247.7 AE 144.6 mg per day (median 200, range 25-700 mg/day) for the polytherapy exposed pregnancies (mean difference 60.8 mg/ day, 95% CI 12.6-109.0 mg per day).
Pregnancies exposed to any of the combinations of topiramate with one or other of these AEDs did not show unequivocally higher malformation rates than those in the remaining topiramate-associated polytherapy pregnancies, although in each case the numbers involved in the comparisons were small.
The malformations associated with topiramate combinations were hypospadias (five times, three of them in offspring of the same woman in consecutive pregnancies, the only instances of previous fetal malformations occurring in the total 34 pregnancies of the 11 women whose pregnancies resulted in topiramate polytherapy-associated malformations); and once each for the following: spina bifida and brain malformation (valproate also involved), nasal atresia, atrial septal defect and hydronephrosis, ventricular septal defect, duplex kidney, skull suture sclerosis, periventricular nodular hyperplasia, tongue tie, and unilateral amblyopia. Thus there appeared to be a tendency for the topiramate polytherapy-related teratogenicity to be associated in particular with hypospadias, but various other morphologic maldevelopments had also occurred.
Discussion
Over the 15 years of the Australian Pregnancy Register's existence there had been major changes in the AED-prescribing pattern for pregnant women, and in the drug dosages used. 9, 10 In particular, following the recognition of the dose-related teratogenicity of valproate and the subsequent attempt to disseminate this knowledge among medical professionals in Australia, in the pregnancies enrolled in the register dosages of the drug had tended to decrease, and there had been an overall trend with time for the rate of occurrence of fetal malformations to decrease. 9, 10 Whether this change in prescribing behavior applied only in that majority of pregnancies that were exposed to single AEDs, or whether it had also occurred in the pregnancies in which AED combinations were taken is unknown.
The present investigation suggests that it is no longer justifiable to hold the idea that the presence of valproate in AED combinations is the sole factor responsible for the reported increased risk of fetal malformation. Here we report evidence that topiramate, when used in polytherapy in early pregnancy, was associated with an increased rate of fetal malformations. The presence of either valproate or topiramate in an AED combination appears to suggest that use of AEDs in combination tends to be associated with a greater risk of teratogenicity than the overall use of AEDs in monotherapy. Consistent with the conclusions of recent reports, [6] [7] [8] it is not the combining of AEDs per se, but the properties of the specific drugs that are combined, that appears to determine the malformation risk. This study provides evidence that topiramate should join valproate as drugs associated with increased fetal malformation risk. However, unlike the situation with valproate, the increased malformation risk with topiramate in the present study appeared restricted to its use in polytherapy, with the risk in monotherapy not elevated compared to AED-unexposed pregnancies.
There have been previously published indications that topiramate may be a teratogen [11] [12] [13] and that it may be responsible for the occurrence of facial clefts and hypospadias. 14 The previous preliminary report from the UK Epilepsy and Pregnancy Register also found that there was a remarkable increase in malformation rate in women who took topiramate in polytherapy (11.2%) as compared with monotherapy (2.2%).
14 In this study, the monotherapy-associated malformation rate (2.4%) appeared lower than the <5% rate reported in other topiramate monotherapy series. 12, [14] [15] [16] In view of this, the appreciably higher (statistically significant) fetal malformation rate associated with the drug's use in polytherapy, even allowing for possible effects of dosage differences, provides evidence that use of topiramate in conjunction with other AEDs may enhance its propensity to cause fetal malformation.
The mechanisms through which topiramate may have enhanced teratogenicity when the drug was taken as a part of AED polytherapy are uncertain. It is possible that a pharmacokinetic interaction with other AEDs may have resulted in the accumulation of a teratogenic metabolite of topiramate. Another possibility is that the mechanism could involve a pharmacodynamic effect of the combination of topiramate and other AEDs. In support of this possibility, topiramate has been shown to induce significant neurotoxicity in the developing rat brain when administered in combination with phenytoin, but not when administered alone. 17 On the basis of the present study, we recommend that, as far as possible, the use of topiramate, at least as part of AED polytherapy, be avoided in women who plan to become pregnant.
